ライフサイエンスコーパス: 5'-nucleotidase

1 nto adenosine by the extracellular CD73/ecto-5-nucleotidase.

2 enuated by treatment of WT mice with soluble 5'-nucleotidase.

3 AP suppresses pain by functioning as an ecto-5'-nucleotidase.

4 is mediated by selective inhibition of ecto-5'-nucleotidase.

5 or potential targets of zinc other than ecto-5'-nucleotidase.

6 ptor agonists or reconstitution with soluble 5'-nucleotidase.

7 l actions of ecto-phosphodiesterase and ecto-5'-nucleotidase.

8 ted with inhibition of SAH hydrolase but not 5'-nucleotidase.

9 dforward ADP-mediated inhibition of the ecto-5'-nucleotidase.

10 ) were all significantly reduced by blocking 5'-nucleotidase.

11 by P-O bond cleavage by phosphatases such as 5'-nucleotidase.

12 utations in the same gene, NT5C2, encoding a 5'-nucleotidase.

13 s specifically blocked by parasite secretory 5'-nucleotidase.

14 d from ischemic neurologic injury by soluble 5'-nucleotidase.

15 t description of autoantibodies to cytosolic 5' nucleotidase 1A in patients with IBM is a potentially

16 nalysis revealed that Mup44 is the cytosolic 5'-nucleotidase 1A (cN1A).

17 e entire human proteome identified cytosolic 5'-nucleotidase 1A (cN1A; NT5C1A) as the likely 43 kDa I

18 to induce AMP-metabolizing enzymes cytosolic 5'-nucleotidase 1A and AMP-deaminase 3, which suppress A

19 Serum autoantibodies against cytosolic 5'-nucleotidase 1A have been identified in IBM showing m

20 antibodies against the GPI-anchored protein 5' nucleotidase (5' NT) at the apical membrane of MDCK c

21 5' nucleotidase (5'N) is a major source of the vasogenic

22 new method for microassay of the activity of 5'-nucleotidase (5'-ND) and adenosine deaminase (ADA) in

23 We demonstrate that soluble 5'-nucleotidase (5'-NT) and alkaline phosphatase (AP) me

24 The adenosine producing enzyme ecto-5'-nucleotidase (5'-NT) is not normally expressed during

25 cluster of differentiation (CD)39] and ecto-5'-nucleotidase (5'-NT; CD73), among others.

26 e that purified, recombinant human cytosolic 5'-nucleotidases (5'-NTs) CN-II and CN-III, but not CN-I

27 (such as carboxylesterase), and PM (such as 5'-nucleotidase [5'-ND]; alkaline phosphatase [AP]; and

28 and enzymatic activity assays indicated that 5'-nucleotidase (5NT), rather than AP, was responsible f

29 ulence factor, which we termed streptococcal 5'-nucleotidase A (S5nA).

30 1A30 recombinant protein cofractionated with 5'-nucleotidase, a classical GPI-anchored membrane marke

31 These estradiol binding-sites co-purify with 5'-nucleotidase, a plasma membrane-marker enzyme, and ar

32 3 wk) elevated plasma zinc and activities of 5'-nucleotidase, a zinc-dependant enzyme, in 20 postmeno

33 mine oxidase-A, nucleotides tri-phosphatase, 5'-nucleotidase, acetylcholine esterase, and myeloperoxi

34 not aminopeptidase N, aminopeptidase P, and 5'-nucleotidase activities.

35 We show that cNIII-like also displays 5' nucleotidase activity with a high affinity for m(7)GM

36 e identified a novel S. pyogenes enzyme with 5'-nucleotidase activity and immune evasion properties.

37 compounds induced a strong inhibition of the 5'-nucleotidase activity in vitro, and the most potent o

38 enzymes possess nicotinamide mononucleotide 5'-nucleotidase activity in vitro.

39 These results not only show that ecto-5'-nucleotidase activity is a critical mediator of metho

40 The NudP ecto-5'-nucleotidase activity is reminiscent of the reactions

41 Because the ecto-5'-nucleotidase activity of CD73 catalyzes AMP breakdown

42 binant NudP revealed a Mn(2+)-dependent ecto-5'-nucleotidase activity on ribo- and deoxyribonucleosid

43 In COS-7 cells, 5'-nucleotidase activity was not rate-limiting for inosi

44 In H9c2 cells, in which 5'-nucleotidase activity was rate-limiting, only cN-II o

45 hate kinase (Ndk), adenylate kinase (Ak) and 5'-nucleotidase activity, the level of secretion of the

46 c supplementation doubled the mean value for 5'-nucleotidase activity, values were still significantl

47 ree thyroxine concentrations and mononuclear 5'-nucleotidase activity.

48 the recombinant and native proteins possess 5'-nucleotidase activity; hence, the protein has been ca

49 a Mono Q column demonstrates the presence of 5'-nucleotidase, adenylate kinase, and a putative ATP re

50 -methylene-ADP, often used to block the ecto-5'-nucleotidase, also inhibited voltage-gated K(+) curre

51 acking A2A adenosine receptor (A2AR) or ecto-5'nucleotidase (an enzyme that converts extracellular AM

52 study tested the hypothesis that CD73 (ecto-5'nucleotidase), an enzyme that catalyzes the conversion

53 lipid rafts marked by GPI-anchored proteins (5' nucleotidase and folate receptor).

54 tion of the apical plasma membrane proteins, 5'-nucleotidase and aminopeptidase N in lysosomal vacuol

55 and inosine monophosphate-specific cytosolic 5'-nucleotidase and an elevation of ecto-5'-nucleotidase

56 at NKT cells express both CD39 and CD73/ecto-5'-nucleotidase and can therefore generate adenosine fro

57 SNPs at the 5'-nucleotidase and xanthine oxidase genes influence the

58 dase activity, the level of secretion of the 5'-nucleotidase (and/or ATPase/phosphatase) appears to b

59 nstrate nucleoside diphosphate kinase (Ndk), 5' nucleotidase, and adenylate kinase (Ak) activities.

60 the following secreted exoenzymes: apyrase, 5'-nucleotidase, and adenosine deaminase.

61 m, adenosine is generated by the enzyme ecto-5'-nucleotidase, and adenosine production and adenosine

62 hate kinase (Ndk), ATPase, adenylate kinase, 5'-nucleotidase, and ATP-modifying enzymatic activities.

63 tein phosphatases, purple acid phosphatases, 5'-nucleotidase, and DNA repair enzymes such as Mre11.

64 tase, protein serine/threonine phosphatases, 5'-nucleotidase, and DNA repair enzymes such as Mre11.

65 ibroblast-like cells (e.g., collagen I, ecto-5'-nucleotidase, and PDGF receptor-beta).

66 sn1, initially classified as an IMP-specific 5'-nucleotidase, and Sdt1, initially classified as a pyr

67 The apical PM proteins aminopeptidase N, 5'nucleotidase, and the polymeric IgA receptor were effi

68 ot with this solution plus a blocker of ecto-5'-nucleotidase (AOPCP).

69 d Sdt1, initially classified as a pyrimidine 5'-nucleotidase, are additionally responsible for dephos

70 A 5'-nucleotidase, as well as hyaluronidase activity, was

71 l muscle fibres and dephosphorylated by ecto 5'nucleotidase bound to the sarcolemma.

72 pression of mRNAs for ENPP1, NTPD1, and ecto-5'-nucleotidase, but not NTPD2 (ecto-ATPase, or CD39L1),

73 in the supernate of cells deficient in ecto-5'-nucleotidase, but there is a marked increase in extra

74 acellular adenosine as generated by the ecto-5'-nucleotidase CD73 in fibrosis development after thora

75 rates AMP, which is in turn used by the ecto-5'-nucleotidase CD73 to synthesize adenosine.

76 An inhibitor of the ecto-5'-nucleotidase CD73, alpha, beta-methylene ADP (AOPCP),

77 The ecto-5'-nucleotidase CD73, an ectoenzyme highly expressed in

78 osine, produced through the activity of ecto-5'-nucleotidase CD73, elicits potent immunosuppressive e

79 exposure reduced the expression of the ecto-5'-nucleotidase CD73, the nicotinamide adenine mononucle

80 e immunosuppressive cell surface enzyme ecto-5'-nucleotidase CD73.

81 In this pathway, ecto-5-nucleotidase CD73 has the unique function of regulatin

82 adenosine monophosphate [AMP]) and CD73 ecto-5'-nucleotidase (CD73 converts AMP to adenosine).

83 accumulation of adenosine and increased ecto-5'-nucleotidase (CD73) and adenosine A(2B) receptor (ADO

84 as "Treg") express apyrases (CD39) and ecto-5'-nucleotidase (CD73) and contribute to their inhibitor

85 lective channel proteins Porin 1 and 2, ecto-5'-nucleotidase (CD73) and Scavenger receptor B1.

86 lized to adenosine by surface-expressed ecto-5'-nucleotidase (CD73) and subsequently activates surfac

87 nt of the purinergic system, the enzyme ecto-5'-nucleotidase (CD73) catalyzes the last step in the ex

88 Ecto-5'-nucleotidase (CD73) catalyzes the terminal phosphohyd

89 Because ecto-5'-nucleotidase (CD73) catalyzes the terminal step in ex

90 ction of anti-inflammatory adenosine by ecto-5'-nucleotidase (CD73) helps maintain endothelial barrie

91 taining, we confirmed the expression of ecto-5'-nucleotidase (CD73) in trigeminal nociceptive neurons

92 We show that inhibition of ecto-5'-nucleotidase (CD73) in vitro reduces carotid body bas

93 Ecto-5'-nucleotidase (CD73) is a central surface enzyme gener

94 Subsequently, we determined that ecto-5'-nucleotidase (CD73) is a key enzyme required for the

95 Ecto-5'-nucleotidase (CD73) is central to the generation of e

96 Ecto-5'-nucleotidase (CD73) is expressed abundantly on the ap

97 The current work evaluated whether ecto-5'-nucleotidase (CD73) is important in promoting carotid

98 Ecto-5'-nucleotidase (CD73) is the main enzyme responsible fo

99 Nucleotide phosphohydrolysis by the ecto-5'-nucleotidase (CD73) is the main source for extracellu

100 nism, K8/K18 accumulation and increased ecto-5'-nucleotidase (CD73) levels were noted.

101 Ecto-5'-nucleotidase (CD73) on immune cells is emerging as a

102 tory response, we evaluated the role of ecto-5'-nucleotidase (CD73) on the development of heart failu

103 39) to AMP, which then is hydrolyzed by ecto-5'-nucleotidase (CD73) to adenosine.

104 In addition, increased activity of ecto-5'-nucleotidase (CD73) was found in the lungs in conjunc

105 In contrast, a subset expressing Ecto-5'-nucleotidase (CD73) was retained and a specific CD73(

106 ate (ATP) diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73) were increased twofold to threefo

107 1 than in the DG, and concentrations of ecto-5'-nucleotidase (CD73) were much higher in CA1.

108 Levels of ecto-5'-nucleotidase (CD73), an enzyme that converts extracel

109 The present study investigated whether ecto-5'-nucleotidase (CD73), an enzyme that generates adenosi

110 Ecto-5'-nucleotidase (CD73), encoded by NT5E, is the major en

111 of the adenosine-generating ectoenzyme, ecto-5'-nucleotidase (CD73), in regulating immune and organ f

112 We investigated whether ecto-5'-nucleotidase (CD73), the "pacemaker" enzyme of extrac

113 Ecto-5'-nucleotidase (CD73), the enzyme that generates adenos

114 We now show that ecto-5'-nucleotidase (CD73), the major enzyme able to convert

115 -monophosphate (AMP) through the enzyme ecto-5'-nucleotidase (CD73), we examined the contribution of

116 ity of the adenosine-generating enzyme, ecto-5'-nucleotidase (CD73), which was significantly lower in

117 triphosphate diphosphohydrolase 1 (CD39) and 5'-nucleotidase (CD73).

118 he terminal enzymatic step catalyzed by ecto-5'-nucleotidase (CD73).

119 phosphate diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73).

120 back) in mice with targeted deletion of ecto-5'-nucleotidase/CD73 (e-5'NT/CD73), the enzyme responsib

121 sphate diphosphohydrolase (NTPDase) and ecto-5'-nucleotidase/CD73 activities in thoracic aortas, lymp

122 iphosphohydrolase-1 (NTPDase1/CD39) and ecto-5'-nucleotidase/CD73 activities were measured in 226 pat

123 ated several structural modifications of the 5'-nucleotidase cDNA, expressed the corresponding protei

124 ed and characterized a novel human cytosolic 5'-nucleotidase (cN-I) that potentially may have an impo

125 Messenger RNA for the cytosolic AMP-specific 5'-nucleotidase (CN-I) was not detected in human bronchi

126 Two, cloned cytosolic 5'-nucleotidases (cN-I and cN-II) have been implicated i

127 now been identified as targeting cytoplasmic 5' nucleotidase (cN1A; NT5C1A), a protein involved in nu

128 This indicates that the 5'-nucleotidase contributes to but is not solely respons

129 e purine metabolism (inosine triphosphatase, 5'-nucleotidase cytosolic-II, purine nucleoside phosphor

130 The 5'-nucleotidase, cytosolic II gene (NT5C2, cN-II) is ass

131 for both hemoglobin E (Hb E) and pyrimidine 5' nucleotidase deficiency are segregating.

132 ptomatic and those homozygous for pyrimidine 5' nucleotidase deficiency have the mild hemolytic anemi

133 hat the hemolysis associated with pyrimidine 5' nucleotidase deficiency results not only from an incr

134 rease in the stability of Hb E in pyrimidine 5' nucleotidase-deficient red blood cells (RBCs).

135 Wild type, ecto-5'-nucleotidase-deficient, and adenosine receptor-defici

136 c stimuli are paired with disruption of ecto-5'-nucleotidase-dependent adenosine production or A1-ade

137 ion of CD39/ENTPD1 in concert with CD73/ecto-5'-nucleotidase distinguishes CD4(+)/CD25(+)/Foxp3(+) T

138 potent against c-N-I than the membrane ecto-5'-nucleotidase (e-N).

139 IMP-specific, High Km 5'-nucleotidase (EC 3.1.3.5) is an ubiquitous enzyme, th

140 ted the conversion of AMP to adenosine: ecto 5'-nucleotidase (ecto 5'-NT, CD73) and alkaline phosphat

141 lic 5'-nucleotidase and an elevation of ecto-5'-nucleotidase (ecto-5'-NT).

142 We aimed to identify inhibitors of ecto-5'-nucleotidase (ecto-5'-NT, CD73), a membrane-bound met

143 ividuals, siRNA of tetraspanin 33 (TSPAN33), 5'-nucleotidase, ecto (NT5E), transmembrane emp24 protei

144 ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of e

145 h) cells correlated with high levels of ecto-5'-nucleotidase enzymatic activity.

146 ucleotidase II gene (NT5C2), which encodes a 5'-nucleotidase enzyme that is responsible for the inact

147 lications have reported attenuated CD73/ecto-5'-nucleotidase expression in patients with EoE, which i

148 subset had the highest levels of CD73 (ecto-5'-nucleotidase) expression (Deltamean fluorescence inte

149 strong in salivary-expressed members of the 5'-nucleotidase family of arthropods because of constrai

150 Members of the 5'nucleotidase family were recruited for salivary expres

151 l, while release of AMP and affinity of ecto 5'nucleotidase for AMP are increased by acidosis.

152 Here we describe a novel 5' nucleotidase from Drosophila that cleaves m(7)GMP to

153 led to the redistribution of syntaxin 2 and 5' nucleotidase from the apical membrane to subapical pu

154 Two SNPs at the 5'-nucleotidase gene were associated with NCPH: rs111915

155 MP-CP), and a competitive substrate for ecto-5'-nucleotidase (guanosine monophosphate, GMP) did not a

156 However, inhibition of 5'-nucleotidase had no effect on ATP/ADP/UTP-induced pho

157 HUVEC express NTPDases, as well as 5'-nucleotidase; hence, nucleotides can be metabolized t

158 used to develop inhibitors of the cytosolic 5'-nucleotidase I (c-N-I) from myocardium.

159 ed the effects of dual deletion of cytosolic 5'-nucleotidases IA (NT5C1A) and II (NT5C2) in mice.

160 Mutations in the cytosolic 5' nucleotidase II (NT5C2) gene drive resistance to thio

161 design potential inhibitors of the cytosolic 5'-nucleotidase II (cN-II), which has been recognized as

162 Activating mutations in cytosolic 5'-nucleotidase II (NT5C2) are considered to drive relap

163 We previously showed that cytosolic 5'-nucleotidase II (NT5C2)-deficient mice were protected

164 cing, we identify mutations in the cytosolic 5'-nucleotidase II gene (NT5C2), which encodes a 5'-nucl

165 ng ABL1 fusions, NOTCH1/FBXW7, and cytosolic 5'-nucleotidase II gene mutations identify patient group

166 e potent inhibiting c-N-I than the cytosolic 5'-nucleotidase II.

167 Cytosolic 5'-nucleotidase III (cN-III) is responsible for selectiv

168 is supported by comparison to YfdR, another 5'-nucleotidase in E. coli.

169 the role of adenosine generated by CD73/ecto-5'-nucleotidase in GVHD.

170 Zinc was a less potent inhibitor of ecto-5'-nucleotidase in vitro than the nucleotide analog alph

171 directly studied the properties of the ecto-5'-nucleotidase in Xenopus embryo spinal cord.

172 Both parasite secreted products and the 5'-nucleotidase inhibit ADP-induced release of mast cell

173 Because ecto 5' nucleotidase inhibitor (alpha,beta-methylene adenosin

174 ted cells to activated neutrophils; the ecto-5'-nucleotidase inhibitor alpha, beta-methylene adenosin

175 ent beads was inhibited by ATP, but the ecto-5'-nucleotidase inhibitor alpha, beta-methylene ADP prev

176 Addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP (200

177 was greatly reduced by addition of the ecto-5'-nucleotidase inhibitor alpha,beta-methylene ADP (200

178 The ecto-5'-nucleotidase inhibitor alphabeta-meADP significantly

179 0.4 +/- 2.8%, while AOPCP (12.5 mm), an ecto-5'-nucleotidase inhibitor that increases extracellular A

180 adenosine activity was clamped by combining 5'-nucleotidase inhibitor with A1-agonist to determine w

181 nflammation, and injection of APCP, the ecto-5'-nucleotidase inhibitor, abrogates completely the incr

182 enosine using a combination of a potent ecto-5'-nucleotidase inhibitor, alpha,beta-methylene adenosin

183 denosine A1 receptor blocker, A1-agonist, or 5'-nucleotidase inhibitor.

184 de transporter inhibitor; APCP, a CD73 (ecto-5'-nucleotidase) inhibitor; or cold adenosine significan

185 EPEC infection by testing the effect of ecto-5'-nucleotidase inhibitors.

186 ic treatments using small-molecule cytosolic 5'-nucleotidase inhibitors.

187 CD73/ecto-5'-nucleotidase is an enzyme that generates adenosine, w

188 ves the PO4 moieties from ATP, likely with a 5'-nucleotidase-like enzyme rather than alkaline phospha

189 We have isolated the 5' region of the ecto-5'-nucleotidase (low K(m) 5'-NT) gene and established th

190 Use of soluble 5'-nucleotidase may be a potential therapeutic for hepat

191 During exercise, the concentration of ecto 5'nucleotidase may be increased by translocation from th

192 vidence that adenosine results from the ecto-5'-nucleotidase- mediated conversion of adenine nucleoti

193 Such fractions, harboring 5' nucleotidase, Ndk, and presumably other ATP-utilizing

194 up B Streptococcus expresses a specific ecto-5'-nucleotidase necessary for its pathogenicity and high

195 that specific NTPDases, in tandem with ecto-5'-nucleotidase, not only terminate P2 receptor activati

196 Ecto-5'-nucleotidase (NT5E) catalyzes dephosphorylation of ex

197 Prostatic acid phosphatase (PAP) and ecto-5'-nucleotidase (NT5E) hydrolyze extracellular AMP to ad

198 Thereby, we demonstrate that ecto-5'-nucleotidase (NT5e) is specifically expressed in STP

199 CD73, an ecto-5'-nucleotidase (NT5E), serves as an immune checkpoint b

200 Ecto-5'-nucleotidase (NT5E, CD73) is a membrane-anchored prot

201 (2B)R) after hydrolysis to adenosine by ecto-5'-nucleotidase (NT5E, CD73) or prostatic acid phosphata

202 obtaining IRB permission, expression of ecto-5'-nucleotidase (NT5E, CD73) was assessed in matched spe

203 n was mediated by altered expression of ecto-5'-nucleotidase (Nt5e, gene encoding for CD73).

204 stimulation mainly by the action of the ecto-5'-nucleotidase, NT5E, and to a lesser extent, prostatic

205 riglyceride content, while mice lacking ecto-5'-nucleotidase or adenosine A1 or A2B receptors were pr

206 he bed bug Cimex lectularius apyrase, (ii) a 5'-nucleotidase/phosphodiesterase, (iii) a hyaluronidase

207 In this study, we show that CD73 (ecto-5'-nucleotidase) plays an important role in regulating t

208 at target the cell-surface enzyme CD73 (ecto-5'-nucleotidase) reduce growth of primary tumors and met

209 econstitution of cd73(-/-) mice with soluble 5'-nucleotidase resulted in complete restoration of hepa

210 Mutations in ushA, encoding a predicted 5'-nucleotidase, resulted in accumulation of flavin aden

211 Like other 5'-nucleotidases, S5nA requires divalent cations and was

212 thway (transformation of AMP to adenosine by 5'-nucleotidase) seems to be the rate-limiting step.

213 ified a cell wall-anchored protein harbors a 5'-nucleotidase signature sequence and evidence strongly

214 dependent transcriptional repression of ecto-5'-nucleotidase, solute carrier family 12 member 8, and

215 ntly facilitated in the presence of the ecto-5'-nucleotidase substrate 5'-AMP.

216 e process of association and dissociation of 5'-nucleotidase subunits.

217 CD73 is an ecto-5' nucleotidase that catalyzes the terminal phosphohydro

218 n by the upstream metabolite ADP of the ecto-5'-nucleotidase that converts AMP to adenosine introduce

219 mice that lack the CD73 gene (encoding ecto-5'-nucleotidase that converts AMP to adenosine) to test

220 CD73 is a cell surface 5'-nucleotidase that converts AMP to adenosine, an immun

221 CD73, an ecto-5'-nucleotidase that converts AMP to adenosine, is funct

222 ed that elevated expression of CD73, an ecto-5'-nucleotidase that generates adenosine, correlates wit

223 CD73 is a cell surface ecto-5'-nucleotidase that generates extracellular adenosine,

224 lectivity for c-N-I versus both of the other 5'-nucleotidases, the nucleoside inhibitors of c-N-I may

225 Eukaryotic pyrimidine 5'-nucleotidase type 1 (P5N-1) catalyzes dephosphorylati

226 or treatment of wild-type mice with soluble 5'-nucleotidase was associated with significantly lower

227 However, the activity of cytosolic 5'-nucleotidase was elevated 6- to 10-fold.

228 The secreted 5'-nucleotidase was identified as a protein with an appa

229 glycophosphatidylinositol-anchored protein, 5'-nucleotidase, were observed, suggesting that increase

230 y degraded into adenosine by ecto-ATPase and 5'-nucleotidase, which have been identified in the canal

231 omain phosphohydrolase, the Escherichia coli 5'-nucleotidase YfbR.

232 ases (ndk, pykA, or pykF) and the gene for a 5'-nucleotidase (yfbR).